Weekly round-up: Optimum’s 16th Annual Healthcare Investor Conference highlights the feel good factor for life sciences in 2025
Optimism has well and truly returned to life sciences and this newfound confidence was reflected in many of the discussions at this year’s Optimum Strategic Communications Healthcare Investor Conference.
Held at the prestigious King’s Fund venue in central London, the great and good of the biotech and pharma industry met to reflect on the events of 2024 and look forward to 2025 and beyond. Catch up on the day’s events with our key take aways article here.
Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer
Commit Biologics, a pioneer in the activation of the complement system to treat cancer and autoimmune disease, on Tuesday announced the appointment of Mikkel Wandahl Pedersen as Chief Scientific Officer (CSO).
Pederson is a highly experienced leader with demonstrated track record of antibody-based drug discovery and pipeline advancement and will spearhead research and development of Commit’s BiCETM technology as the Company moves towards drug candidate nomination.
Biocomposites invests in InfectoTest GmbH – developers of a bacterial-specific point-of-care test for periprosthetic joint infection (PJI)
Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, on Wednesday announced that it had taken a minority-share interest in InfectoTest GmbH, a biomedical company based in Berlin that is developing innovative point-of-care systems for the diagnosis of infectious diseases.
One of InfectoTest’s lead products in development is InfectoSynovia, a rapid and high-accuracy test that will detect a periprosthetic joint infection (PJI) in less than five minutes.
AMSilk Announces Successful Partnership Negotiation with Ajinomoto for Industrial Fermentation
AMSilk GmbH, a frontrunner in advanced biomaterials made from spider silk-based proteins, announced on Wednesday that it is looking to establish a long-term partnership with Ajinomoto Foods Europe, a company with over 50 years of experience in industrial fermentation and the affiliate of the globally established Ajinomoto Group, to biomanufacture silk proteins at their manufacturing facility in Nesle, France.
4SC publishes Q3 2024 report
4SC AG, a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), on Thursday published its Q3 2024 report, presenting all material developments up to 30 September 2024, as well as the Company’s current outlook. The full report is available for download on 4SC’s website.
